{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:22:33Z","timestamp":1792588953752,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bevacizumab is a monoclonal antibody (mAb) that prevents the growth of new blood vessels and is currently employed in the treatment of colorectal cancer (CRC). However, like other mAb, bevacizumab shows a limited penetration in the tumors, hampering their effectiveness and inducing adverse reactions. The aim of this work was to design and evaluate albumin-based nanoparticles, coated with dextran, as carriers for bevacizumab in order to promote its accumulation in the tumor and, thus, improve its antiangiogenic activity. These nanoparticles (B-NP-DEX50) displayed a mean size of about 250\u00a0nm and a payload of about 110\u00a0\u00b5g\/mg. In a CRC mice model, these nanoparticles significantly reduced tumor growth and increased tumor doubling time, tumor necrosis and apoptosis more effectively than free bevacizumab. At the end of study, bevacizumab plasma levels were higher in the free drug group, while tumor levels were higher in the B-NP-DEX50 group (2.5-time higher). In line with this, the biodistribution study revealed that nanoparticles accumulated in the tumor core, potentially improving therapeutic efficacy while reducing systemic exposure. In summary, B-NP-DEX can be an adequate alternative to improve the therapeutic efficiency of biologically active molecules, offering a more specific biodistribution to the site of action.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-024-01734-3","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T14:02:28Z","timestamp":1729864948000},"page":"2354-2371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-0341","authenticated-orcid":false,"given":"Cristina","family":"Pangua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1523","authenticated-orcid":false,"given":"Socorro","family":"Espuelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Ander","family":"Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-1084","authenticated-orcid":false,"given":"Cristina","family":"Mart\u00ednez-Oh\u00e1rriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-1470","authenticated-orcid":false,"given":"Mar\u00eda","family":"Collantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-976X","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Pe\u00f1uelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-4242","authenticated-orcid":false,"given":"Alfonso","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-3436","authenticated-orcid":false,"given":"Juan M.","family":"Irache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"1734_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)32319-0.","journal-title":"Lancet"},{"key":"1734_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu YP. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:1\u20137. https:\/\/doi.org\/10.1016\/j.tranon.2021.101174.","journal-title":"Transl Oncol"},{"key":"1734_CR3","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1001\/jama.2016.6828.Estimation","volume":"315","author":"AB Knudsen","year":"2016","unstructured":"Knudsen AB, Zauber ABAG, Rutter AGCM, Naber CMSK, Doria-Rose SKVP, Pabiniak VPC, Johanson CC, Fischer CSE, Lansdorp-Vogelaar SEI, Kuntz IKM. Estimation of benefits, Burden, and Harms of Colorectal Cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315:2595\u2013609. https:\/\/doi.org\/10.1001\/jama.2016.6828.Estimation.","journal-title":"JAMA"},{"key":"1734_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(21)00199-6","volume":"22","author":"R Cardoso","year":"2021","unstructured":"Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, Van Damme N, Valerianova Z, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021;22:1002\u201313. https:\/\/doi.org\/10.1016\/S1470-2045(21)00199-6.","journal-title":"Lancet Oncol"},{"key":"1734_CR5","doi-asserted-by":"publisher","unstructured":"Janani B, Vijayakumar M, Priya K, Kim JH, Prabakaran DS, Shahid M, Al-Ghamdi S, Alsaidan M, Othman Bahakim N, Hassan Abdelzaher M, Ramesh T. EGFR-Based targeted therapy for colorectal Cancer \u2014 promises and challenges, Vaccines. 2022;10:499. https:\/\/doi.org\/10.3390\/vaccines10040499","DOI":"10.3390\/vaccines10040499"},{"key":"1734_CR6","doi-asserted-by":"publisher","unstructured":"Falk AT, Barri\u00e8re J, Fran\u00e7ois E, Follana P, Bevacizumab. A dose review. Crit Rev Oncol Hematol. 2015;94:311\u201322. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2015.01.012.","DOI":"10.1016\/J.CRITREVONC.2015.01.012"},{"key":"1734_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11523-017-0518-1","volume":"12","author":"LS Rosen","year":"2017","unstructured":"Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: current role in treatment and the potential of Biosimilars. Target Oncol. 2017;12:599\u2013610. https:\/\/doi.org\/10.1007\/s11523-017-0518-1.","journal-title":"Target Oncol"},{"key":"1734_CR8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","volume":"54","author":"TA Wichelmann","year":"2021","unstructured":"Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED. Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting System (FAERS) database. Aliment Pharmacol Ther. 2021;54:1290\u20137. https:\/\/doi.org\/10.1111\/apt.16601.","journal-title":"Aliment Pharmacol Ther"},{"key":"1734_CR9","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Anti-tumour Treatment Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017.","journal-title":"Cancer Treat Rev"},{"key":"1734_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fonc.2020.00221","volume":"10","author":"Y Haibe","year":"2020","unstructured":"Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, Shamseddine A. Resistance mechanisms to anti-angiogenic therapies in Cancer. Front Oncol. 2020;10:221. https:\/\/doi.org\/10.3389\/fonc.2020.00221.","journal-title":"Front Oncol"},{"key":"1734_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40824-018-0133-y","volume":"22","author":"W Park","year":"2018","unstructured":"Park W, Heo YJ, Han DK. New opportunities for nanoparticles in cancer immunotherapy. Biomaters Res. 2018;22:24. https:\/\/doi.org\/10.1186\/s40824-018-0133-y.","journal-title":"Biomaters Res"},{"key":"1734_CR12","doi-asserted-by":"publisher","first-page":"2009860","DOI":"10.1002\/adfm.202009860","volume":"31","author":"TG Dacoba","year":"2021","unstructured":"Dacoba TG, Anthiya S, Berrecoso G, Fern\u00e1ndez-Mari\u00f1o I, Fern\u00e1ndez-Varela C, Crecente-Campo J, Teijeiro-Osorio D, And\u00f3n FT, Alonso MJ. Nano-Oncologicals: a Tortoise Trail reaching New avenues. Adv Funct Mater. 2021;31:2009860. https:\/\/doi.org\/10.1002\/adfm.202009860.","journal-title":"Adv Funct Mater"},{"key":"1734_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/jpm11080771","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J. The enhanced permeability and Retention (EPR) Effect: the significance of the Concept and methods to enhance its application. J Pers Med. 2021;11:771. https:\/\/doi.org\/10.3390\/jpm11080771.","journal-title":"J Pers Med"},{"key":"1734_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jconrel.2016.07.028","volume":"238","author":"R Ngoune","year":"2016","unstructured":"Ngoune R, Peters A, von Elverfeldt D, Winkler K, P\u00fctz G. Accumulating nanoparticles by EPR: a route of no return. J Control Release. 2016;238:58\u201370. https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.028.","journal-title":"J Control Release"},{"key":"1734_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.20517\/cdr.2020.68","volume":"3","author":"I Hassanin","year":"2020","unstructured":"Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020;3:930\u201346. https:\/\/doi.org\/10.20517\/cdr.2020.68.","journal-title":"Cancer Drug Resist"},{"key":"1734_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fphys.2014.00299","volume":"5","author":"AM Merlot","year":"2014","unstructured":"Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 2014;5:299. https:\/\/doi.org\/10.3389\/fphys.2014.00299.","journal-title":"Front Physiol"},{"key":"1734_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.02.003","volume":"541","author":"I Luis de Red\u00edn","year":"2018","unstructured":"Luis de Red\u00edn I, Boiero C, Mart\u00ednez-Oh\u00e1rriz MC, Ag\u00fceros M, Ramos R, Pe\u00f1uelas I, Allemandi D, Llabot JM, Irache JM. Human serum albumin nanoparticles for ocular delivery of bevacizumab. Int J Pharm. 2018;541:214\u201323. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.02.003.","journal-title":"Int J Pharm"},{"key":"1734_CR18","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","volume":"18","author":"A Spada","year":"2021","unstructured":"Spada A, Emami J, Tuszynski JA, Lavasanifar A. The uniqueness of Albumin as a carrier in Nanodrug Delivery. Mol Pharm. 2021;18:1862\u201394. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00046.","journal-title":"Mol Pharm"},{"key":"1734_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0378-5173(03)00134-0","volume":"257","author":"K Langer","year":"2003","unstructured":"Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003;257:69\u2013180. https:\/\/doi.org\/10.1016\/S0378-5173(03)00134-0.","journal-title":"Int J Pharm"},{"key":"1734_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/ph13090235","volume":"13","author":"D Kim","year":"2020","unstructured":"Kim D, Lee SS, Yoo WY, Moon H, Cho A, Park SY, Kim YS, Kim HR, Lee HJ. Combination therapy with doxorubicin-loaded reduced albumin nanoparticles and focused ultrasound in mouse breast cancer xenografts. Pharmaceuticals. 2020;13:235. https:\/\/doi.org\/10.3390\/ph13090235.","journal-title":"Pharmaceuticals"},{"key":"1734_CR21","doi-asserted-by":"publisher","first-page":"e2104012","DOI":"10.1002\/advs.202104012","volume":"9","author":"N Habibi","year":"2022","unstructured":"Habibi N, Mauser A, Ko Y, Lahann J. Protein nanoparticles: uniting the power of proteins with Engineering Design approaches. Adv Sci Adv Sci (Weinh). 2022;9:e2104012. https:\/\/doi.org\/10.1002\/advs.202104012.","journal-title":"Adv Sci Adv Sci (Weinh)"},{"key":"1734_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/15563650.2020.1832231","volume":"59","author":"S Thumtecho","year":"2021","unstructured":"Thumtecho S, Sriapha C, Tongpoo A, Udomsubpayakul U, Wananukul W, Trakulsrichai S. Poisoning of glutaraldehyde-containing products: clinical characteristics and outcomes. Clin Toxicol. 2021;59:480\u20137. https:\/\/doi.org\/10.1080\/15563650.2020.1832231.","journal-title":"Clin Toxicol"},{"key":"1734_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ijbiomac.2016.05.032","volume":"91","author":"A Jahanban-Esfahlan","year":"2016","unstructured":"Jahanban-Esfahlan A, Dastmalchi S, Davaran S. A simple improved desolvation method for the rapid preparation of albumin nanoparticles. Int J Biol Macromol. 2016;91:703\u20139. https:\/\/doi.org\/10.1016\/j.ijbiomac.2016.05.032.","journal-title":"Int J Biol Macromol"},{"key":"1734_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.22037\/ijpr.2015.1639","volume":"14","author":"H Niknejad","year":"2015","unstructured":"Niknejad H, Mahmoudzadeh HR. Comparison of different crosslinking methods for preparation of docetaxel-loaded albumin nanoparticles. Iran J Pharm Res. 2015;14:385\u201394. https:\/\/doi.org\/10.22037\/ijpr.2015.1639.","journal-title":"Iran J Pharm Res"},{"key":"1734_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2014.11.042","volume":"482","author":"N Grabowski","year":"2015","unstructured":"Grabowski N, Hillaireau H, Vergnaud J, Tsapis N, Pallardy M, Kerdine-R\u00f6mer S, Fattal E. Surface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophages. Int J Pharm. 2015;482:75\u201383. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.11.042.","journal-title":"Int J Pharm"},{"key":"1734_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jddst.2019.04.042","volume":"52","author":"JM Llabot","year":"2019","unstructured":"Llabot JM, Luis de Redin JMI, Ag\u00fceros M IM, D\u00e1vila Caballero MJ, Boiero MJC, Irache CJM. D. Allemandi, in vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV). J Drug Deliv Sci Technol. 2019;52:379\u201385. https:\/\/doi.org\/10.1016\/j.jddst.2019.04.042.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1734_CR27","doi-asserted-by":"publisher","first-page":"107697","DOI":"10.1016\/j.exer.2019.107697","volume":"185","author":"I Luis de Red\u00edn","year":"2019","unstructured":"Luis de Red\u00edn I, Boiero C, Recalde S, Ag\u00fceros M, Allemandi D, Llabot JM, Garc\u00eda-Layana A, Irache JM. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization. Exp Eye Res. 2019;185:107697. https:\/\/doi.org\/10.1016\/j.exer.2019.107697.","journal-title":"Exp Eye Res"},{"key":"1734_CR28","doi-asserted-by":"publisher","first-page":"119289","DOI":"10.1016\/J.IJPHARM.2020.119289","volume":"581","author":"AL Mart\u00ednez-L\u00f3pez","year":"2020","unstructured":"Mart\u00ednez-L\u00f3pez AL, Pangua C, Reboredo C, Campi\u00f3n R, Morales-Gracia J, Irache JM. Protein-based nanoparticles for drug delivery purposes. Int J Pharm. 2020;581:119289. https:\/\/doi.org\/10.1016\/J.IJPHARM.2020.119289.","journal-title":"Int J Pharm"},{"key":"1734_CR29","doi-asserted-by":"publisher","first-page":"10748","DOI":"10.1039\/D1NR02065J","volume":"13","author":"L Shi","year":"2021","unstructured":"Shi L, Zhang J, Zhao M, Tang S, Cheng X, Zhang W, Li W, Liu X, Wang PH. Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery. Nanoscale. 2021;13:10748\u201364. https:\/\/doi.org\/10.1039\/D1NR02065J.","journal-title":"Nanoscale"},{"key":"1734_CR30","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","volume":"75","author":"B Schaefer","year":"2020","unstructured":"Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020;75:100862. https:\/\/doi.org\/10.1016\/j.mam.2020.100862.","journal-title":"Mol Aspects Med"},{"key":"1734_CR31","doi-asserted-by":"publisher","unstructured":"Diaz-Montes E, Dextran. Sources, structures, and Properties. Polysaccharides. 2021;2:554\u201365. https:\/\/doi.org\/10.3390\/polysaccharides2030033.","DOI":"10.3390\/polysaccharides2030033"},{"key":"1734_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ejpb.2012.03.009","volume":"81","author":"K Alhareth","year":"2012","unstructured":"Alhareth K, Vauthier C, Bourasset F, Gueutin C, Ponchel G, Moussa F. Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles. Eur J Pharm Biopharm. 2012;81:453\u20137. https:\/\/doi.org\/10.1016\/j.ejpb.2012.03.009.","journal-title":"Eur J Pharm Biopharm"},{"key":"1734_CR33","doi-asserted-by":"publisher","unstructured":"Zhang Y, Huo M, Zhou J, Xie S, PKSolver. An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306\u201314. https:\/\/doi.org\/10.1016\/j.cmpb.2010.01.007.","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"1734_CR34","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1002\/cam4.3939","volume":"10","author":"M Dahan","year":"2021","unstructured":"Dahan M, Hequet D, Bonneau C, Paoletti X, Rouzier R. Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review. Cancer Med. 2021;10:5203\u201317. https:\/\/doi.org\/10.1002\/cam4.3939.","journal-title":"Cancer Med"},{"key":"1734_CR35","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1158\/0008-5472.CAN-06-3822","volume":"67","author":"E Mehrara","year":"2007","unstructured":"Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67:3970\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3822.","journal-title":"Cancer Res"},{"key":"1734_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3332\/ecancer.2016.617","volume":"10","author":"F Arvelo","year":"2016","unstructured":"Arvelo F, Sojo F, Cotte C. Tumour progression and metastasis. Ecancermedicalscience. 2016;10:617. https:\/\/doi.org\/10.3332\/ecancer.2016.617.","journal-title":"Ecancermedicalscience"},{"key":"1734_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/cancers11030316","volume":"11","author":"Y Katayama","year":"2019","unstructured":"Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K. Tumor neovascularization and developments in therapeutics. Cancers (Basel). 2019;11:316. https:\/\/doi.org\/10.3390\/cancers11030316.","journal-title":"Cancers (Basel)"},{"key":"1734_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.20892\/j.issn.2095-3941.2020.0704","volume":"18","author":"BM Bordeau","year":"2021","unstructured":"Bordeau BM, Balthasar JP. Strategies to enhance monoclonal antibody uptake and distribution in solid tumors. Cancer Biol Med. 2021;18:649\u201364. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0704.","journal-title":"Cancer Biol Med"},{"key":"1734_CR39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421\u201334. https:\/\/doi.org\/10.1016\/j.addr.2008.04.012.","journal-title":"Adv Drug Deliv Rev"},{"key":"1734_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/BTT.S166310","volume":"13","author":"E Cruz","year":"2019","unstructured":"Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019;13:33\u201351. https:\/\/doi.org\/10.2147\/BTT.S166310.","journal-title":"Biologics"},{"key":"1734_CR41","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.apsb.2021.03.033","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang M, Gao S, Yang D, Fang Y, Lin X, Jin X, Liu Y, Liu X, Su K, Shi K. Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. Acta Pharm Sin B. 2021;11:2265\u201385. https:\/\/doi.org\/10.1016\/j.apsb.2021.03.033.","journal-title":"Acta Pharm Sin B"},{"key":"1734_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2013.08.001","volume":"89","author":"A Lluch","year":"2014","unstructured":"Lluch A, Alvarez I, Mu\u00f1oz M, Segu\u00ed M\u00c1, Tusquets I, Garc\u00eda-Est\u00e9vez L. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. Crit Rev Oncol Hematol. 2014;89:62\u201372. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.001.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1734_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nnano.2014.17","volume":"9","author":"Z Wang","year":"2014","unstructured":"Wang Z, Li J, Cho J, Malik AB. Prevention of vascular inflammation by nanoparticle targeting of Adherent Neutrophils. Nat Nanotechnol. 2014;9:204\u201310. https:\/\/doi.org\/10.1038\/nnano.2014.17.","journal-title":"Nat Nanotechnol"},{"key":"1734_CR44","doi-asserted-by":"publisher","first-page":"145103","DOI":"10.1088\/0957-4484\/26\/14\/145103","volume":"26","author":"E Fahrl\u00e4nder","year":"2015","unstructured":"Fahrl\u00e4nder E, Schelhaas S, Jacobs AH, Langer K. PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterization and quantification of the PEGylation extent. Nanotechnology. 2015;26:145103. https:\/\/doi.org\/10.1088\/0957-4484\/26\/14\/145103.","journal-title":"Nanotechnology"},{"key":"1734_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154\u2013155","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154\u2013155:163\u201375. https:\/\/doi.org\/10.1016\/j.addr.2020.07.024.","journal-title":"Adv Drug Deliv Rev"},{"key":"1734_CR46","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","volume":"341","author":"M Estap\u00e9 Senti","year":"2022","unstructured":"Estap\u00e9 Senti M, de Jongh CA, Dijkxhoorn K, Verhoef JJF, Szebeni J, Storm G, Hack CE, Schiffelers RM, Fens MH, Boross P. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Control Release. 2022;341:475\u201386. https:\/\/doi.org\/10.1016\/j.jconrel.2021.11.042.","journal-title":"J Control Release"},{"issue":"3","key":"1734_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1248\/bpb.b13-00661","volume":"37","author":"F Zhang","year":"2014","unstructured":"Zhang F, Liu MR, Wan HT. Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull. 2014;37(3):335\u20139. https:\/\/doi.org\/10.1248\/bpb.b13-00661.","journal-title":"Biol Pharm Bull"},{"key":"1734_CR48","doi-asserted-by":"publisher","first-page":"e10600","DOI":"10.1002\/btm2.10600","volume":"9","author":"Y Gao","year":"2023","unstructured":"Gao Y, Joshi M, Zhao Z, Mitragotri S, Bioeng Transl M. PEGylated therapeutics in the clinic. Bioeng Transl Med. 2023;9:e10600. https:\/\/doi.org\/10.1002\/btm2.10600.","journal-title":"Bioeng Transl Med"},{"key":"1734_CR49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jnci\/djj070","volume":"98","author":"MR Dreher","year":"2006","unstructured":"Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, Accumulation, and penetration of Macromolecular Drug Carriers. J Natl Cancer Inst. 2006;98:335\u201344. https:\/\/doi.org\/10.1093\/jnci\/djj070.","journal-title":"J Natl Cancer Inst"},{"key":"1734_CR50","doi-asserted-by":"publisher","first-page":"374252","DOI":"10.1155\/2013\/374252","volume":"2013","author":"S Salmaso","year":"2013","unstructured":"Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv. 2013;2013:374252. https:\/\/doi.org\/10.1155\/2013\/374252.","journal-title":"J Drug Deliv"},{"key":"1734_CR51","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3390\/polym14132601","volume":"14","author":"V Ejigah","year":"2022","unstructured":"Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the enhanced permeability and Retention Effect. Polym (Basel). 2022;14:2601. https:\/\/doi.org\/10.3390\/polym14132601.","journal-title":"Polym (Basel)"},{"key":"1734_CR52","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1039\/D0BM00556H","volume":"8","author":"A Bai\u00e3o","year":"2020","unstructured":"Bai\u00e3o A, Sousa F, Oliveira AV, Oliveira C, Sarmento B. Effective intracellular delivery of bevacizumab via PEGylated polymeric nanoparticles targeting CD44v6 receptor in colon cancer cells. Biomater Sci. 2020;8:3720\u20139. https:\/\/doi.org\/10.1039\/D0BM00556H.","journal-title":"Biomater Sci"},{"key":"1734_CR53","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1038\/s41598-017-03959-4","volume":"7","author":"F Sousa","year":"2017","unstructured":"Sousa F, Cruz A, Fonte P, Pinto IM, Neves-Petersen MT, Sarmento B. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci Rep. 2017;7:3736. https:\/\/doi.org\/10.1038\/s41598-017-03959-4.","journal-title":"Sci Rep"},{"key":"1734_CR54","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/jbm.a.36424","volume":"106","author":"P Badiee","year":"2018","unstructured":"Badiee P, Varshochian R, Rafiee-Tehrani M, Abedin Dorkoosh F, Khoshayand MR, Dinarvand R. Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment. J Biomed Mater Res A. 2018;106:2261\u201371. https:\/\/doi.org\/10.1002\/jbm.a.36424.","journal-title":"J Biomed Mater Res A"},{"key":"1734_CR55","doi-asserted-by":"publisher","first-page":"e0151874","DOI":"10.1371\/journal.pone.0151874","volume":"11","author":"YY Zhao","year":"2016","unstructured":"Zhao YY, Wang N, Liu WH, Tao WJ, Liu LL, Shen ZD. Charge variants of an Avastin Biosimilar isolation, characterization, in Vitro properties and pharmacokinetics in Rat. PLoS ONE. 2016;11:e0151874. https:\/\/doi.org\/10.1371\/journal.pone.0151874.","journal-title":"PLoS ONE"},{"key":"1734_CR56","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s13346-020-00722-7","volume":"10","author":"I Luis de Red\u00edn","year":"2020","unstructured":"Luis de Red\u00edn I, Exp\u00f3sito F, Ag\u00fceros M, Collantes M, Pe\u00f1uelas I, Allemandi D, Llabot JM, Calvo A, Irache JM. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer. Drug Deliv Transl Res. 2020;10:635\u201345. https:\/\/doi.org\/10.1007\/s13346-020-00722-7.","journal-title":"Drug Deliv Transl Res"},{"key":"1734_CR57","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941\u201351. https:\/\/doi.org\/10.1038\/nbt.3330.","journal-title":"Nat Biotechnol"},{"key":"1734_CR58","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1016\/j.bioactmat.2021.03.008","volume":"6","author":"Y Zeng","year":"2021","unstructured":"Zeng Y, Xiang Y, Sheng R, Tom H. Bioactive materials polysaccharide-based nanomedicines for cancer immunotherapy: a review. Bioact Mater. 2021;6:3358\u201382. https:\/\/doi.org\/10.1016\/j.bioactmat.2021.03.008.","journal-title":"Bioact Mater"},{"key":"1734_CR59","doi-asserted-by":"publisher","first-page":"371","DOI":"10.18433\/J3N590","volume":"17","author":"S Pustylnikov","year":"2014","unstructured":"Pustylnikov S, Sagar D, Jain P, Khan ZK. Targeting the C-type lectins-mediated host-Pathogen interactions with Dextran. J Pharm Pharm Sci. 2014;17:371\u201392. https:\/\/doi.org\/10.18433\/J3N590.","journal-title":"J Pharm Pharm Sci"},{"key":"1734_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.biomaterials.2005.04.041","volume":"27","author":"C Lemarchand","year":"2006","unstructured":"Lemarchand C, Gref R, Passirani C, Garcion E, Petri B, M\u00fcller R, Costantini D, Couvreur P. Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials. 2006;27:108\u201318. https:\/\/doi.org\/10.1016\/j.biomaterials.2005.04.041.","journal-title":"Biomaterials"},{"key":"1734_CR61","doi-asserted-by":"publisher","first-page":"487316","DOI":"10.3389\/fphar.2021.487316","volume":"12","author":"C C\u0103inap","year":"2021","unstructured":"C\u0103inap C, Bochi\u015f OV, Vlad C, Popita R, Achima\u015f-Cadariu P, Havasi A, Vidrean A, Dranca A, Piciu A, Constantin AM, Tat T, Dana M, Cri\u015fan O, Cioban CV, B\u0103l\u0103cescu O, Coza O, B\u0103l\u0103cescu L, Marta MM, Bota M, C\u0103inap S. Doubling the dose of Bevacizumab Beyond Progression in metastatic colorectal Cancer \u2013 the experience of a Tertiary Cancer Center. Front Pharmacol. 2021;12:487316. https:\/\/doi.org\/10.3389\/fphar.2021.487316.","journal-title":"Front Pharmacol"},{"key":"1734_CR62","doi-asserted-by":"publisher","first-page":"880","DOI":"10.4329\/wjr.v8.i11.880","volume":"8","author":"K Kawada","year":"2016","unstructured":"Kawada K, Iwamoto M, Sakai Y. Mechanisms underlying 18 F-fluorodeoxyglucose accumulation in colorectal cancer. World J Radiol. 2016;8:880\u20136. https:\/\/doi.org\/10.4329\/wjr.v8.i11.880.","journal-title":"World J Radiol"},{"key":"1734_CR63","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/ph12010016","volume":"12","author":"H O\u2019Neill","year":"2019","unstructured":"O\u2019Neill H, Malik V, Johnston C, Reynolds JV, O\u2019Sullivan J. Can the efficacy of [18F]FDG-PET\/CT in clinical oncology be enhanced by screening biomolecular profiles? Pharmaceuticals (Basel). 2019;12:1612. https:\/\/doi.org\/10.3390\/ph12010016.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1734_CR64","doi-asserted-by":"publisher","first-page":"1801840","DOI":"10.1002\/adfm.201801840","volume":"28","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Wang H, Tan T, Li J, Wang Z, Li Y. Rational design of nanoparticles with deep tumor penetration for effective treatment of Tumor Metastasis. Adv Funct Mater. 2018;28:1801840. https:\/\/doi.org\/10.1002\/adfm.201801840.","journal-title":"Adv Funct Mater"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01734-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01734-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01734-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T08:25:10Z","timestamp":1749025510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01734-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01734-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5044027\/v1","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"18 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed. The protocols were approved by the \u201cEthical and Biosafety Committee for Research on Animals\u201d (protocols number 066\u2009\u2212\u200916, 113\u2009\u2212\u200921, and 090\u2009\u2212\u200922).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}